Drug fusions and conjugates
US8779103B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 24, 2010 |
| Grant date | Jul 15, 2014 |
| Priority date | — |
| Expiry date | Aug 26, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/569
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and GLP and/or exendin molecules. The invention further relates to uses, formulations, compositions and devices comprising such drug fusions and conjugates.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.